With New Wegovy Data In Hand, Novo Nordisk Will File For Approval In MASH
Reuters/hollie adams/file photo purchase licensing rights. Novo intends to seek approvals of semaglutide in mash in the u. s. And europe in the first half of 2025. “we are very pleased about the essence clinical trial results and the. Novo nordisk expects part 2 of the study will post data in 2029.
Food and drug administration (fda) has approved an additional indication for wegovy. Novo nordisk’s weight loss drug wegovy helped people with a fatty liver disease called mash experience.